News
VTVT
23.84
+0.17%
0.04
Viking Therapeutics gains on early data for oral weight loss therapy
Seeking Alpha · 2d ago
Weekly Report: what happened at VTVT last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at VTVT last week (0311-0315)?
Weekly Report · 03/18 12:25
vTv Therapeutics Appoints Anne Phillips, Reshuffles Board Committees
Anne Phillips has joined vTv Therapeutics, Inc. As a new independent director. She will also lead the Compensation Committee and serve on the Audit Committee. VTVT stock is down 10% in the last week. The company's stock price has risen to $7.
TipRanks · 03/14 12:12
vTv Therapeutics Q4 EPS $(1.67) Up From $(2.28) YoY
Benzinga · 03/13 12:03
VTv Therapeutics: Q4 Earnings Snapshot
VTv Therapeutics Inc. On Wednesday reported a loss of $3.5 million in its fourth quarter. The High Point, North Carolina-based company said it had a Loss of $1.67 per share. For the year, the company reported a losses of $20.3 million.
Barchart · 03/13 07:23
Weekly Report: what happened at VTVT last week (0304-0308)?
Weekly Report · 03/11 12:20
12 Health Care Stocks Moving In Tuesday's After-Market Session
NKGen Biotech (NASDAQ:NKGN) stock increased by 62.4% to $1.4 during Tuesday's after-market session. VTv Therapeutics stock moved upwards by 13.17%. Cerus ( NASDAQ:CERS) increased by 9.09% during the day. The company's, Q4 earnings came out today.
Benzinga · 03/05 21:31
vTv Therapeutics Enhances Investor Communication with Update
TipRanks · 03/05 13:23
Weekly Report: what happened at VTVT last week (0226-0301)?
Weekly Report · 03/04 12:24
vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference
VTv Therapeutics Inc. Is focused on the development of cadisegliatin as an adjunctive therapy to insulin for the treatment of type 1 diabetes. Company management will be presenting at the TD Cowen 44th Annual Healthcare Conference in 2024. The presentation is scheduled for March 5, 2024.
Barchart · 03/01 07:00
S&P 500 Edges Lower; ADT Posts Upbeat Earnings
The Dow Jones index fell around 100 points on Wednesday. U.S. Stocks traded lower toward the end of trading. ADT Inc. Reported better-than-expected earnings for its fourth quarter. Vivani Medical, Inc. Shares shot up 274% to $3.78. Asian markets closed lower in Asia Pacific markets.
Benzinga · 02/28 19:30
BUZZ-U.S. STOCKS ON THE MOVE-Shift4 Payments, Chart Industries, Applied Therapeutics
Wall Street's main indexes slipped on Wednesday. Dow Jones Industrial Average was down 0.10% at 38,933.98. Top three S&P 500 percentage gainers: Axon Enterprise, eBay. The top three Nasdaq percentage losers: Chart Industries, Applied Therapeutics.
Reuters · 02/28 19:26
Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Bumble Inc. (NASDAQ:BMBL) fell sharply after the company reported weak quarterly results. Vivani Medical, Inc. Shares jumped 289% to $3.93 during Wednesday's mid-day session. Bumble reported quarterly losses of 19 cents per share which missed the analyst consensus estimate.
Benzinga · 02/28 19:02
Why Is Diabetes Focused vTv Therapeutics Stock Trading Higher Today?
VTv Therapeutics Inc (NASDAQ:VTVT) shares are soaring on a robust session volume of 2.7 million. The company closed a private placement to healthcare-focused institutional investors for $51 million. VTv has a pipeline of clinical drug candidates for type 1 diabetes.
Benzinga · 02/28 18:53
VTv Therapeutics Shares Surge on $51 Million Private Placement
Shares of vTv Therapeutics more than doubled after the company raised $51 million in a private placement. The stock was at $17.48 on Wednesday. The money will be used to fund the first Phase 3 study of its lead product candidate. Cadisegliatin is in development for the treatment of type 1 diabetes.
Dow Jones · 02/28 17:57
12 Health Care Stocks Moving In Wednesday's Intraday Session
Vivani Medical (NASDAQ:VANI) stock increased by 314.4% to $4.19 during Wednesday's regular session. The company's market cap stands at $213.5 million. Adial Pharmaceuticals and vTv Therapeutics moved upwards by 157.73% and 105.88% respectively. Losers Oragenics (AMEX:OGEN) and Novavax stock declined by 42.9%.
Benzinga · 02/28 17:31
Nasdaq Down 50 Points; US Crude Stocks Rise By 4.2M Barrels
U.S. Stocks traded lower midway through trading on Wednesday. The Dow traded down 0.19% while the NASDAQ fell 0.31%. Vivani Medical, Inc. Shares shot up 301% to $4.05; real estate shares rose by 1.1% in trading. Crude oil inventories increased by 4.199 million barrels in the week ending Feb. 23, the EIA said. Asian markets closed lower; European shares were mostly lower.
Benzinga · 02/28 17:25
BUZZ-U.S. STOCKS ON THE MOVE-Permian Resources, Vivani, Incannex
Wall Street's main indexes slip ahead of inflation reading later in the week. Dow Jones Industrial Average down 0.29% at 38,858.67. Top three S&P 500 percentage gainers: Axon Enterprise, Ebay; top three percentage losers: Eventbrite, Viatris.
Reuters · 02/28 15:50
VTV Therapeutics Inc Says Entered Into A Sales Agreement With Cowen And Company; Pursuant To Agreement Co May Offer And Sell Shares Of Class A Common Stock Having Aggregate Offering Price Of Up To $50.0M
Benzinga · 02/28 14:32
More
Webull provides a variety of real-time VTVT stock news. You can receive the latest news about Vtv Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About VTVT
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for diabetes. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non-central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes HPP593, Nrf2/Bach1 Modulator Program, Azeliragon and HPP3033.